Lantern Pharma Inc.
NASDAQ:LTRNBiotechnology
-$0.19 today
- Market cap
- $50.14M
- Beta
- 2.32
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.41
Volume 0.10M
Average 0.68M
LTRN Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How LTRN compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 27.2% | — | -36963.4 pp | |
| LTM Mar 2026 | -864.3% | +3970.7 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding LTRN) | -418.6% | +3970.7 pp | -36963.4 pp | |
Competitors are the stored peer set for LTRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 174.84K | 0 | 0 |
| Gross Profit | 0 | 0 | (174.84K) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.57M | 8.6M | 11.89M | 16.13M | 11.51M |
| Selling, General & Admin | 5.02M | 5.83M | 5.98M | 6.09M | 6.46M |
| Operating Expenses | 12.59M | 14.43M | 17.7M | 22.22M | 17.98M |
| Depreciation & Amortization | 6.76K | 10.08K | 174.84K | 17.28K | 17.28K |
| EBITDA | (12.36M) | (14.05M) | (15.79M) | (20.76M) | (17.1M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (12.59M) | (14.43M) | (17.88M) | (22.22M) | (17.98M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 67.93K | 204.36K | 765.39K | 742.36K | 437.93K |
| Interest Expense | 0 | 204.36K | 0 | 0 | 0 |
| Other Income / Expenses | 228.48K | 172.81K | 1.92M | 1.44M | 859.06K |
| Income Before Tax | (12.36M) | (14.26M) | (15.96M) | (20.78M) | (17.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.36M) | (14.26M) | (15.96M) | (20.78M) | (17.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.13) | (1.31) | (1.47) | (1,930.92) | (1.57) |
| EPS (Diluted) | (1.13) | (1.31) | (1.47) | (1,930.92) | (1.57) |
| Weighted Avg Shares | 10.9M | 10.85M | 10.84M | 10.76M | 10.9M |
| Weighted Avg Shares (Diluted) | 10.9M | 10.85M | 10.84M | 10.76M | 10.9M |
Lantern Pharma Inc.
NASDAQ:LTRN
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.